The U.S. Food and Drug Administration has published safety labeling changes made prescribing information for 48 products in November.
Changes were made to boxed warnings, contraindications, warnings, precautions, adverse reactions, patient package insert and medication guide.
The following drugs had modifications to the boxed warnings, contraindications and warnings sections:
- Cerebyx (fosphenytoin sodium)
- Dilantin (phenytoin sodium, USP)
- Dilantin (phenytoin)
- Kombiglyze XR (saxagliptin/metformin hydrochloride extended-release)
- Mytelase (ambenonium chloride)
- Onglyza (saxagliptin)
- Amturnide (aliskiren/amlodipine/hydrochlorothiazide)
- Combivir (lamivudine/zidovudine)
- Emtriva (emtricitabine)
- Epivir (lamivudine)
- Epzicom (abacavir sulfate and lamivudine)
- Isentress (raltegravir potassium)
- Lioresal Intrathecal (baclofen injection)
- Methotrexate Sodium for Injection
- Retrovir (zidovudine)
- Tekamlo (aliskiren/amlodipine)
- Toviaz (fesoterodine fumarate)
- Tribenzor (olmesartan medoxomil, amlodipine, hydrochlorothiazide)
- Trizivir (abacavir sulfate, lamivudine, and zidovudine)
- Twynsta (telmisartan/amlodipine)
- VFEND (voriconazole)
- Videx (didanosine)
- Videx EC (didanosine, USP)
- Vimovo (naproxen/esomeprazole magnesium)
- Viread (tenofovir disoproxil fumarate)
- Zerit (stavudine)
- Ziagen (abacavir sulfate)
- Zyflo CR (zileuton)
To view a listing of drug names and safety labeling sections revised, click here. Clicking on a drug product name in the Summary View will take you to the "detailed view" page, which identifies safety labeling sections and subsections revised, along with a brief summary of new or modified safety information.
Related Articles on Medication Safety:
CMS Issues Revised '30-Minute Rule' on Administration of Medication
Patient Education Tool: 10 Tips to Prevent Accidental Medicine Overdose